DaVita Venture Group

DaVita Venture Group is the corporate venture capital arm of DaVita Inc., a leading global healthcare provider. The firm is dedicated to investing in, acquiring, and co-developing innovative products, solutions, and businesses aimed at enhancing care for patients with kidney disease and related conditions. Their strategic investment priorities encompass advancements in care delivery models, life sciences, and digital health, with a focus on expanding access to care, improving clinical outcomes through tech-enabled services, home treatments, and value-based care, as well as developing pharmaceuticals, medical devices, and diagnostics that reduce costs and improve patient experience.

The firm was officially launched by DaVita in May 2020 as part of its ongoing commitment to transform patient care. DaVita Venture Group was established to accelerate the development and deployment of solutions designed to improve the health and quality of life for individuals with kidney disease and other chronic conditions. Key figures like Steve Phillips, Group Vice President of Strategy and Innovation, and Mahesh Krishnan, Group Vice President of Research and Development, have been instrumental in leading the group's mission to drive innovation beyond traditional dialysis.

DaVita Venture Group actively invests in early-to-mid stage, growth-oriented businesses, typically participating in Series A and beyond funding rounds with individual investments ranging from $1 million to $10 million. Their portfolio includes notable companies such as Greater Good Health, Pathalys Pharma, Xeltis, Wellth, Heartbeat, Dock Health, Miromatrix, eGenesis, Vynca, Nephrosant, ConsejoSano, and MedSleuth. The firm often co-invests and takes an active role in its portfolio companies, frequently through board observerships or director roles.

The team at DaVita Venture Group comprises approximately 13 members, bringing diverse expertise in healthcare strategy, research and development, mergers and acquisitions, strategic partnerships, and pharma strategy. Beyond capital, the firm provides substantial support to its portfolio companies, leveraging DaVita's extensive clinical and operational expertise, value-based care delivery insights, product development resources, data insights, and assistance with business development, hiring, and technical support.